Eicosanoids in Human Heart Failure

Recruiting

• Conditions: Heart Failure
• Interventions: Diagnostic Test: Levels of EETs, DHETs and HETEs

• Registration Number: NCT05305170
• Lead Sponsor: University Hospital, Motol

Brief Summary

Our translational project aims to evaluate the role of eicosanoids in human HF.

Detailed Description

Heart failure (HF) is the leading cause of cardiovascular hospitalizations, and with its increasing prevalence, the healthcare systems face a heart failure pandemic. Translational research findings improve our knowledge of pathophysiology and uncover therapeutic targets in HF. Natriuretic peptides represent such examples as routinely used in diagnostics and therapeutics (neprilysin inhibitor). Despite modern pharmacotherapy, including angiotensin receptor-neprilysin inhibitor (ARNI) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), the prognosis of patients, especially with advanced heart failure, remains poor. Furthermore, most medication is limited in the late stages of HF due to their hypotensive effects.

Basic research has been focused on the eicosanoids - metabolites of cytochrome P-450 (CYP)-dependent epoxygenase pathway of arachidonic acid (AA), especially epoxyeicosatrienoic acids (EETs). In the preclinical studies, it was shown that EETs importantly contribute to the regulation of cardiovascular and renal function and exert organ-protective actions. It was also proposed that intrarenal EETs operate as an endogenous compensatory system opposing increased renin-angiotensin system (RAS) activity. EETs are rapidly transformed by soluble epoxide hydrolase (sEH) to biologically inactive dihydroxyeicosatrienoic acids (DHETs). The role of eicosanoids in human HF, however, remains unclear.

Our translational project (Eicosanoids in Human Heart Failure) aims to evaluate the role of eicosanoids in human HF.

Study Timeline

• Study Start: 2021-08-01
• Status Verified: 2022-03
• Study First Submitted: 2022-03-22
• Study First Submitted QC: 2022-03-22
• Study First Posted: 2022-03-31
• Last Update Submitted: 2022-03-31
• Last Update Posted: 2022-04-08
• Primary Completion: 2023-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Heart failure

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
HF	Levels of EETs, DHETs and HETEs	Patients with heart failure.
Controls	Levels of EETs, DHETs and HETEs	Controls without heart failure.

Primary Outcome Measures

Name	Time	Method
Plasmatic levels of eicosanoids	at enrollment	EET, DHET, 20-HETE

Secondary Outcome Measures

Name	Time	Method
Mortality	2 years	Overall mortality

Trial Locations

Locations (1)

University Hospital Motol; 🇨🇿 Prague, Czechia